{
  "docId": "019de076-a4b3-719a-94d2-ca29be1b4679",
  "docSlug": "0f14c676100503df3bb87c658cc9d332",
  "documentTitle": "Fusion Pharmaceuticals | Investor Presentation Deck | 26 slides",
  "authorId": "fusion-pharmaceuticals",
  "authorName": "Fusion Pharmaceuticals",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 7,
  "pageCount": 26,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide uses a process flow diagram to illustrate the transition from Phase 2 (n=60) to Phase 3 (n=550).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-a4b3-719a-94d2-ca29be1b4679/7",
  "deckHref": "/decks/019de076-a4b3-719a-94d2-ca29be1b4679",
  "deckJsonHref": "/decks/019de076-a4b3-719a-94d2-ca29be1b4679.json",
  "deckAnchorHref": "/decks/019de076-a4b3-719a-94d2-ca29be1b4679#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.96,
        "x": 0.02,
        "y": 0.5
      },
      "kind": "diagram",
      "text": "Phase 2 (n=60) to Phase 3 (n=550) trial design flow",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "09caa133-f36f-4ee6-a19a-e5b276a92e81",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.85,
        "x": 0.03,
        "y": 0.26
      },
      "kind": "list",
      "text": "Based on literature and TATCIST data 100 kBq/kg administered every 8 weeks is known to be a safe and active dose regimen. Opportunity to further optimize benefit/risk ratio FPI-2265 prior to initiating the Phase 3 portion of the study. Exploring alternate regimens with higher dosing frequency while keeping cumulative dose and duration of treatment the same. Phase 3 design based on prior precedents: Pivotal open label randomized controlled study of FPI-2265",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e7b87b33-fc71-4a01-85fb-098c89c1b68c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.75,
        "x": 0.13,
        "y": 0.16
      },
      "kind": "paragraph",
      "text": "Trial designed to select the recommended Phase 3 regimen; completion of enrollment of Phase 2 portion in 2024, consistent with original timelines",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "621bbbc6-3f6f-4f0c-a6b5-f813d0d653b6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.5,
        "x": 0.03,
        "y": 0.07
      },
      "kind": "title",
      "text": "Phase 2/3 Study Initiation Expected in Q2 2024",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cdf874d0-06bd-4389-86e6-6bbf1ce2b6cb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.03,
        "y": 0.02
      },
      "kind": "title",
      "text": "Fusion Aligns with FDA on Potential Registrational Pathway",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6ad6d627-9f96-472c-b8b4-87de92b7775d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "2c08b602-6e25-49b8-8c9d-5624fd5db3c8",
      "evidence": "The slide depicts a sequential clinical trial design flow from Phase 2 to Phase 3.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 9,
      "from": 6,
      "beatId": "6b3d8599-8ead-4bdc-8ad3-1f9f808d7851",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The document presents the solution, including the TATCIST study and Phase 2/3 study initiation",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}